De-escalating axillary management after neoadjuvant chemotherapy in breast cancer: The ratio of positive sentinel lymph nodes matters
Sofía Aragón-Sánchez(Universidad Complutense de Madrid), Reyes Oliver Pérez(Universidad Complutense de Madrid), Beatriz García-Chapinal(Research Institute Hospital 12 de Octubre), Rodrigo Sánchez-Bayona(Research Institute Hospital 12 de Octubre), Lucia Parrilla-Rubio(Universidad Complutense de Madrid), P. Zaragoza-Ballester(Research Institute Hospital 12 de Octubre), L. Álvaro-Valiente(Research Institute Hospital 12 de Octubre), Eva Ciruelos-Gil(Universidad Complutense de Madrid), Laura López-Marín(Research Institute Hospital 12 de Octubre), Alberto Galindo(Universidad Complutense de Madrid)
Cited by 4
Related Papers
International Fetal Cardiac Intervention Registry
|Journal of the American College of Cardiology|2015|161
Risk factors associated with adverse fetal outcomes in pregnancies affected by Coronavirus disease 2019 (COVID-19): a secondary analysis of the WAPM study on COVID-19
|Journal of Perinatal Medicine|2020|158
Lauren subtypes of advanced gastric cancer influence survival and response to chemotherapy: real-world data from the AGAMENON National Cancer Registry
|British Journal of Cancer|2017|106
Neoadjuvant Immune Checkpoint Inhibitors Plus Chemotherapy in Early Breast Cancer
|JAMA Oncology|2024|77
Circulating tumor DNA reveals complex biological features with clinical relevance in metastatic breast cancer
|Nature Communications|2023|65